Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-04-22 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思第二届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 19th meeting of the 2nd Board of Directors of Hangzhou Anjiesi Medical Technology Co., Ltd. It includes multiple agenda items such as approval of the 2024 annual general manager work report, board work report, audit committee reports, financial statements, profit distribution plan, remuneration plans, reappointment of auditors, stock incentive plans, amendments to the company charter, and proposals for the upcoming 2024 annual shareholders meeting. The document is a formal board meeting resolution announcement, detailing management and board decisions, including nominations for board members and approval of financial reports to be submitted to the shareholders. It does not contain the full annual report or financial statements themselves but references that these reports are disclosed separately on the stock exchange website. The document is primarily about board and management information, including board meeting resolutions and management reports to be submitted to shareholders. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-04-22 Chinese
安杰思公司章程
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Company Articles of Association" or "Company Bylaws." It contains detailed chapters on company governance, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other internal rules. It references Chinese company law and securities law, and includes detailed provisions on the organization and operation of the company. There is no indication that this is an annual report, financial statement, or any other type of financial or regulatory filing. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial and contains the full text of the governance rules, not just an announcement or summary, so it is not a report publication announcement or regulatory filing. Confidence is high due to the clear nature of the document as company bylaws.
2025-04-22 Chinese
安杰思关于调整募投项目内部投资结构的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the adjustment of the internal investment structure of its fundraising projects. It details the original fundraising amounts, the adjustments made to the allocation of funds within specific projects, the reasons for these adjustments, and the approval process including board and supervisory committee meetings. It also includes opinions from the supervisory board and the sponsor's verification report. The document does not contain financial statements or comprehensive financial data but is a regulatory announcement about changes in the use of previously raised capital. It is not a full financial report, earnings release, or management discussion, but rather a capital/financing update related to the use of raised funds. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters and contains detailed information about fundraising and capital allocation adjustments, not just a notice of report publication or certification, so it is not RPA or RNS.
2025-04-22 Chinese
安杰思2025年“提质增效重回报”行动方案
Board/Management Information Classification · 95% confidence The document is a detailed proposal from the board of directors of Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the 2025 special action plan titled 'Quality Improvement, Efficiency Enhancement, and Return to Shareholders.' It discusses company strategy, R&D, talent development, market expansion, governance, investor relations, and dividend distribution plans. The document is dated April 21, 2025, and is presented as a formal agenda item for shareholder approval. It includes financial return plans such as dividend distribution and share repurchase but does not contain actual financial statements or quarterly/yearly financial results. It is a formal board proposal or management plan document rather than a financial report or earnings release. The document is not a short announcement or a certification letter but a substantive management plan. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or plans from the company's board or senior management, including strategic action plans and proposals for shareholder approval.
2025-04-22 Chinese
安杰思监事会关于公司2025年限制性股票激励计划相关事项的核查意见
Regulatory Filings Classification · 90% confidence The document is a supervisory board's verification opinion regarding the company's 2025 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and the plan's alignment with shareholder interests. It is not a financial report, earnings release, or regulatory filing per se, but rather a formal opinion related to a stock incentive plan. This fits best under Regulatory Filings (RNS) as it is a compliance and verification statement rather than a direct financial or management report.
2025-04-22 Chinese
安杰思2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including total assets, net profit, earnings per share, and quarterly breakdowns. It also includes management discussion and analysis sections, risk factors, business overview, industry analysis, and shareholder information. The document is about 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of audited financial data and comprehensive company information aligns with the characteristics of an Annual Report (10-K). Therefore, the document is classified as an Annual Report (10-K). FY 2024
2025-04-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.